Rezvan RAZMANDEH, Ensieh NASLI-ESFAHANI, Peyvand AMINI, Robabeh GHODSSI-GHASSEMABADI, Bagher LARIJANI

Effect of treatment of iron deficiency anemia onhemoglobin A1c in type 2 diabetic patients

Background/aim: Iron deficiency anemia (IDA) affects hemoglobin A1c (HbA1c) levels. This study aimed to evaluate the effect of treatment of iron deficiency anemia on hemoglobin A1c in type 2 diabetic patients. Materials and methods: Ninety type 2 diabetes mellitus (T2DM) patients with IDA were included in a randomized, placebo-controlled, single-blind clinical trial. The intervention group (n = 45) received 200 mg/day oral iron for 3 months and the control group (n = 45) received an oral placebo for the same period. Fasting blood sugar, complete blood count, and HbA1c were measured for all subjects at the beginning and the end of the trial. Results: The mean age of the treatment and control group was 51.47 ± 1.05 and 52 ± 1.1 years, respectively. The two groups were not statistically significantly different with regard to diabetes duration (P = 0.436) and age (P = 0.617). Hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin, serum iron, ferritin, total iron-binding capacity, and HbA1c were significantly improved in the intervention group in comparison with the control group (P = 0.005). Conclusion: Iron status should be considered during the interpretation of the HbA1c concentrations in diabetes mellitus. Iron replacement therapy can decrease HbA1c in anemic patients with IDA and T2DM.

PDF

___

1. Ahmad J, Rafat D. HbA1c and iron deficiency: a review. Diabetes Metab Synd 2013; 7: 118-122.
2. Higgins T. HbA1c - An analyte of increasing importance. Clin Biochem 2012; 45: 1038-1045.
3. Herman WH, Cohen RM. Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for the diagnosis of diabetes. J Clin Endocrinol Metab 2012; 97: 1067-1072.
4. Villar E, Lièvre M, Kessler M, Lemaître V, Alamartine E, Rodier M, François M, Zaoui P, Moranne O, Choukroun G et al. Anemia normalization in patients with type 2 diabetes and chronic kidney disease: results of the NEPHRODIAB2 randomized trial. J Diab Complicat 2011; 25: 237-243.
5. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2014; 37 (Suppl. 1): S14-S80.
6. Andrews M, Arredondo M. Ferritin levels and hepcidin mRNA expression in peripheral mononuclear cells from anemic type 2 diabetic patients. Biol Trace Elem Res 2012; 149: 1-4.
7. Scott DA, Fisher AM. The insulin and the zinc content of normal and diabetic pancreas. J Clin Invest 1938; 17: 725-728.
8. Lemaire K, Ravier MA, Schraenen A, Creemers JW, Van de Plas R, Granvik M, Van Lommel L, Waelkens E, Chimienti F, Rutter GA et al. Insulin crystallization depends on zinc transporter ZnT8 expression, but is not required for normal glucose homeostasis in mice. P Natl Acad Sci USA 2009; 106: 14872-1487.
9. Facchini FS, Saylor KL. A low-iron-available, polyphenolenriched, carbohydrate-restricted diet to slow progression of diabetic nephropathy. Diabetes 2003; 52: 1204-1209.
10. Qian P, Guo J, Liu C, Niu Y, Cheng S. Effect of iron on peroxidation and non-enzymatic glycation in diabetic rats. Wei Sheng Yan Jiu 2003; 32: 446-448 (in Chinese with abstract in English).
11. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 2004; 291: 711-717.
12. Kilpatrick ES, Rigby AS, Atkin SL. The relationship between mean glucose and HbA1c in premenopausal women compared with males in the Diabetes Control and Complications Trial. Diabet Med 2008; 25: 112-113.
13. Ng JM, Cooke M, Bhandari S, Atkin SL, Kilpatrick ES. The Effect of iron and erythropoietin treatment on the A1c of patients with diabetes and chronic kidney disease. Diabetes Care 2010; 33: 2310-2313.
14. Hardikar PS, Joshi SM, Bhat DS, Raut DA, Katre PA, Lubree HG, Jere A, Pandit AN, Fall CH, Yajnik CS. Spuriously high prevalence of prediabetes diagnosed by HbA1c in young Indians partly explained by hematological factors and iron deficiency anemia. Diabetes Care 2012; 35: 797-802.
15. Skali H, Lin J, Pfeffer MA, Chen CY, Cooper ME, McMurray JJ, Nissenson AR, Remuzzi G, Rossert J, Parfrey PS et al. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis 2013; 61: 238-246.
16. Thomas S, Rampersad M. Anaemia in diabetes. Acta Diabetol 2004; 41: S13-S7.
17. Gillum RF. Association of serum ferritin and indices of body fat distribution and obesity in Mexican American men--the Third National Health and Nutrition Examination Survey. Int J Obesity Related Metab Dis 2001; 25: 639-645.
18. Horton BF, Huisman TH. Studies on the heterogeneity of hemoglobin. Br J Haematol 1965; 11: 296-304.
19. Fernández-Real JM, López-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 2002; 51: 2348-2354.
20. Brooks AP, Metcalfe J, Day JL, Edwards MS. Iron deficiency and glycosylated haemoglobin A. Lancet 1980; 2: 141.
21. Gram-Hansen P, Eriksen J, Mourits-Andersen T, Olesen L. Glycosylated haemoglobin (HbA1c) in iron- and vitamin B12 deficiency. J Intern Med 1990; 227: 133-136.
22. Coban E, Ozdogan M, Timuragaoglu A. Effect of iron deficiency anemia on the levels of hemoglobin A1c in nondiabetic patients. Acta Haematol 2004; 112: 126-128.
23. Salonen JT, Tuomainen TP, Nyyssonen K, Lakka HM, Punnonen K. Relation between iron stores and non-insulin dependent diabetes in men: case-control study. BMJ 1998; 317: 727.
24. Rafat D, Rabbani TK, Ahmad J, Ansari MA. Influence of iron metabolism indices on HbA1c in non-diabetic pregnant women with and without iron-deficiency anemia: effect of iron supplementation. Diabetes Metab Syndr 2012; 6: 102-105.
25. Tarim O, Kucukerdogan A, Gunay U, Eralp O, Ercan I. Effects of iron deficiency anemia on hemoglobin A1c in type 1 diabetes mellitus. Pediatr Int 1999; 41: 357-362.
26. Davidson MB, Schriger DL. Effect of age and race/ethnicity on HbA1c levels in people without known diabetes mellitus: implications for the diagnosis of diabetes. Diabetes Res Clin Pract 2010; 87: 415-421.
27. Hashimoto K, Noguchi S, Morimoto Y, Hamada S, Wasada K, Imai S, Murata Y, Kasayama S, Koga M. A1C but not serum glycated albumin is elevated in late pregnancy owing to iron deficiency. Diabetes Care 2008; 31: 1945-1948.
28. Hashimoto K, Osugi T, Noguchi S, Morimoto Y, Wasada K, Imai S, Murata Y, Kasayama S, Koga M. A1C but not serum glycated albumin is elevated because of iron deficiency in late pregnancy in diabetic women. Diabetes Care 2010; 33: 509- 511.
29. Arredondo M, Fuentes M, Jorquera D, Candia V, Carrasco E, Leiva E, Mujica V, Hertrampf E, Pérez F. Cross-talk between body iron stores and diabetes: iron stores are associated with activity and microsatellite polymorphism of the heme oxygenase and type 2 diabetes. Biol Trace Elem Res 2011; 143: 625-636.
30. Saudek CD, Herman WH, Sacks DB, Bergenstal RM, Edelman D, Davidson MB. A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab 2008; 93: 2447- 2453.
31. Davis RE, Nicol DJ. Glycosylated haemoglobin and diabetic control. Ann Acad Med Singapore 1980; 9: 54-59.
32. Koga M, Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. Endocr J 2010; 57: 751-762.
33. Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004; 27: 2422-2428.
34. Dinneen SF, Silverberg JD, Batts KP, OBrien PC, Ballard DJ, Rizza RA. Liver iron stores in patients with non-insulindependent diabetes mellitus. Mayo Clin Proc 1994; 69: 13-15.
35. Hernandez C, Lecube A, Carrera A, Simo R. Soluble transferrin receptors and ferritin in type 2 diabetic patients. Diabet Med 2005; 22: 97-101.